The importance of clinical grading of heart failure and other cardiac toxicities during chemotherapy: updating the common terminology criteria for clinical trial reporting

• Published in: Heart failure clinics Vol. 7; no. 3; p. 373
• Main Authors: Hossain, Akm, Chen, Alice, Ivy, Percy, Lenihan, Daniel J, Kaltman, Jonathan, Taddei-Peters, Wendy, Remick, Scot C
• Format: Journal Article
• Language: English
• Published: United States 01.07.2011
• Subjects: Antineoplastic Agents - adverse effects; Antineoplastic Agents - classification; Cardiotoxins - adverse effects; Cardiotoxins - classification; Cardiovascular Diseases - chemically induced; Cardiovascular Diseases - diagnosis; Cardiovascular Diseases - physiopathology; Cardiovascular Diseases - prevention & control; Drug-Related Side Effects and Adverse Reactions - classification; Drug-Related Side Effects and Adverse Reactions - diagnosis; Drug-Related Side Effects and Adverse Reactions - prevention & control; Early Diagnosis; Humans; Neoplasms - drug therapy; Patient Selection; Risk Assessment - classification; Risk Factors; Severity of Illness Index; Terminology as Topic
• ISSN: 1551-7136
• DOI: 10.1016/j.hfc.2011.03.008

Although the use of chemotherapy and targeted therapy has improved the clinical benefit, progression-free survival, and overall survival of various cancers in recent years, old and new toxicities have limited their use. To balance the risk with the benefit of treatment, Common Toxicity Criteria and now Common Terminology Criteria for Adverse Events (CTCAE) have been used by the oncology community for more than 20 years to assess toxicity from cancer treatment. This article details the description and grading of cardiac toxicities reported in association with cancer treatment and the use of CTCAE to assess them.